DEST announced that Sir Nigel Rudd will step down as Chairman and as a member of the board with effect from 31 December 2018. Nick Rodgers, Non-executive Director of DEST, will succeed him as Chairman.
Nick Rodgers is currently Chairman of SEHTA, one of the largest health technology networking organisations in the UK. Previously, he served as Non-executive Director and then Chairman of Oxford Biomedica plc, a biopharmaceutical company.
The directorate changed today at Destiny is part of the normal progression and maturing of a biotech company. Having just initiated coverage on Destiny Pharma, their management and the board led by Sir Nigel Rudd clearly have accomplished much and should be proud of their accomplishments to date. Having known Nick Rogers all the way back to his Beeson Gregory days, I’m sure that he will build on Sir Nigel’s tenure and we look forward to continuing to work with Nick and the team at Destiny.
Neil Clark, CEO of DEST, commented: “On behalf of Destiny Pharma, I would like to thank Sir Nigel for his considerable contribution to the company, which has grown significantly as a result of his extensive experience, specialised industry knowledge and track record of developing early stage companies. We wish Sir Nigel all the very best for the future. On behalf of Destiny Pharma, I also welcome Nick as Chairman and look forward to continuing to work closely with him as we advance our XF-drug platform through clinical development.”